{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:21:09Z","timestamp":1774426869948,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011441","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000}}],"reference-count":63,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011441.pub2","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T09:23:52Z","timestamp":1506331432000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors"],"prefix":"10.1002","volume":"2020","author":[{"given":"Chatree","family":"Chai-Adisaksopha","sequence":"first","affiliation":[{"name":"McMaster University; Hamilton Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J","family":"Nevitt","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy L","family":"Simpson","sequence":"additional","affiliation":[{"name":"Rush University Medical Center; Section of Pediatric Hematology\/Oncology; 1653 W Congress Parkway Chicago USA IL 60612"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maissaa","family":"Janbain","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine; Department of Hematology & Medical Oncology; 1430 Tulane Avenue New Orleans Louisiana USA LA 70112"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A","family":"Konkle","sequence":"additional","affiliation":[{"name":"921 Terry Avenue; Bloodworks North West; Seattle Washington USA WA 98104"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"10.1002\/14651858.CD011441.pub2-BIB0001|cit1","first-page":"982","article-title":"A prospective, open-label, randomized, parallel study with AICC to evaluate the efficacy and safety of prophylactic vs. on-demand treatment in hemophilia A or B subjects with inhibitors","volume":"11 Suppl 2","author":"Antunes","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hae.12246","article-title":"Comparison of historic on-demand versus prospective on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD011441.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2013","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0004|cit4","first-page":"719","article-title":"Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from the AICC prophylaxis study","volume":"11 Suppl 2","author":"Stasyshyn","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"5","key":"10.1002\/14651858.CD011441.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/hae.12390","article-title":"Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study","volume":"20","author":"Stasyshyn","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA in prophylactic therapy","volume":"22","author":"Varadi","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0007|cit7","first-page":"588","article-title":"Evidence of APCC mode of action in a clinical study treating hemophilia A inhibitor patients with prophylaxis therapy","volume":"13 Suppl 2","author":"Varadi","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1002\/14651858.CD011441.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2516.2008.01654.x","article-title":"Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors","volume":"14","author":"Hoots","year":"2008","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011441.pub2-BIB0009|cit9","first-page":"14","article-title":"Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment","volume":"12","author":"Konkle","year":"2006","journal-title":"Haemophilia"},{"issue":"11","key":"10.1002\/14651858.CD011441.pub2-BIB0010|cit10","article-title":"Secondary prophylaxis with rFVIIa improves quality of life of hemophilia patients with inhibitors and frequent bleeds","volume":"108","author":"Konkle","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD011441.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"11","key":"10.1002\/14651858.CD011441.pub2-BIB0012|cit12","article-title":"Randomized, prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilla patients with inhibitors","volume":"108","author":"Konkle","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0013|cit13","unstructured":"Fusco F Gringeri A Leissinger C Cortesi PA Mantovani LG Bleeding prophylaxis with an anti-inhibitor coagulant complex (AICC) in patients with hemophilia A and inhibitors can improve quality of life: results of the PRO-FEIBA Study 16th Congress of the European Hematology Association; 2011 June 9-12; London, UK 2011"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0014|cit14","first-page":"927","article-title":"Bleeding prophylaxis with an anti-inhibitor coagulant complex (AICC) in patients with hemophilia a and inhibitors can improve quality of life: results of the pro-FEIBA study","volume":"9 Suppl 2","author":"Gringeri","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"5","key":"10.1002\/14651858.CD011441.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.12178","article-title":"Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: Results from the Pro-FEIBA study","volume":"19","author":"Gringeri","year":"2013","journal-title":"Haemophilia"},{"issue":"21","key":"10.1002\/14651858.CD011441.pub2-BIB0016|cit16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4187.4187","article-title":"Cost-effectiveness of prophylaxis with anti-inhibitor complex concentrate in patients with hemophilia A and inhibitors: results from the Pro-FEIBA study","volume":"118","author":"Gringeri","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0017|cit17","first-page":"70","article-title":"Pharmacoeconomic evaluation with an activated prothrombin complex concentrate (APCC) in patients with hemophilia and inhibitors (PRO-FEIBA Study)","volume":"18 Suppl 3","author":"Gringeri","year":"2012","journal-title":"Haemophilia"},{"issue":"18","key":"10.1002\/14651858.CD011441.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0019|cit19","first-page":"31","article-title":"A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data","volume":"16 Suppl 4","author":"Leissinger","year":"2010","journal-title":"Haemophilia"},{"issue":"21","key":"10.1002\/14651858.CD011441.pub2-BIB0020|cit20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.720.720","article-title":"Prophylactic dosing of anti-inhibitor coagulant complex (FEIBA) reduces bleeding frequency in hemophilia A patients with inhibitors: results of the Pro-FEIBA study","volume":"118","author":"Leissinger","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD011441.pub2-BIB0021|cit21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3374.3374","article-title":"Joint disease and the potential for improved joint health in inhibitor patients who have a good response to aPCC prophylaxis: data from the profeiba study","volume":"120","author":"Leissinger","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0022|cit22","unstructured":"NCT00221195 Efficacy study of activated prothrombin complex for prevention of bleeds in hemophilia clinicaltrials.gov\/ct2\/show\/NCT00221195"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0023|cit23","first-page":"179","article-title":"Health-related quality of life (HRQOL) in bleeding prophylaxis with an activated prothrombin complex concentrate (APCC): results from the Pro-FEIBA study","volume":"18 Suppl 3","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0024|cit24","first-page":"28","article-title":"Quality of life in pro-FEIBA study","volume":"18 Suppl 1","author":"Riva","year":"2012","journal-title":"Haemophilia"},{"issue":"7","key":"10.1002\/14651858.CD011441.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jth.12237","article-title":"40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors","volume":"11","author":"Ljung","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0026|cit26","unstructured":"NCT00951405 Safety and efficacy of 3 different doses of long acting factor VII in haemophilia A or B patients with inhibitors clinicaltrials.gov\/ct2\/show\/NCT00951405"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0027|cit27","unstructured":"NCT02622321 A study to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in hemophilia A patients with inhibitors (HAVEN 1) clinicaltrials.gov\/ct2\/show\/NCT02622321"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0028|cit28","unstructured":"NCT02795767 A study of once-weekly emicizumab in children and adolescents with hemophilia A and Factor VIII (FVIII) inhibitors (HAVEN 2) clinicaltrials.gov\/ct2\/show\/NCT02795767"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0029|cit29","unstructured":"NCT02847637 A clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in hemophilia A participants without inhibitors (HAVEN 3) clinicaltrials.gov\/ct2\/show\/NCT02847637"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0030|cit30","unstructured":"NCT03020160 A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab given every 4 weeks in participants with hemophilia A (Haven 4) clinicaltrials.gov\/ct2\/show\/NCT03020160"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0031|cit31","unstructured":"NCT01105546 rFVIIa prophylaxis in children with hemophilia A and inhibitors (ENJOIH) ClinicalTrials.gov\/show\/NCT01105546"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"102","key":"10.1002\/14651858.CD011441.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2516.2008.01923.x","article-title":"Inhibitor development: patient-determined risk factors","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD011441.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2006.01359.x","article-title":"Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference","volume":"12 Suppl 6","author":"Berntorp","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2516.2000.00380.x","article-title":"Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection","volume":"6","author":"Chuansumrit","year":"2000","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1002\/14651858.CD011441.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99","volume":"2","author":"Darby","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0040|cit40","unstructured":"Deeks J Higgins J Altman D Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011441.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7650","key":"10.1002\/14651858.CD011441.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2516.1998.440558.x","article-title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A","volume":"4","author":"Hay","year":"1998","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD011441.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-2000-8453","article-title":"Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000","volume":"26","author":"Hedner","year":"2000","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0046|cit46","unstructured":"Higgins JPT Altman DG editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0047|cit47","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the CSMG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011441.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD011441.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004449.pub3","article-title":"Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors","author":"Iorio","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011441.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub4","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Iorio","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD011441.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","article-title":"A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0053|cit53","unstructured":"National Hemophilia Foundation MASAC recommendation regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors www.hemophilia.org\/Researchers-Healthcare-Providers\/Medical-and-Scientific-Advisory-Council-MASAC\/MASAC-Recommendations\/MASAC-Recommendation-Regarding-Prophylaxis-with-Bypassing-Agents-in-Patients-with-Hemophilia-and-High-Titer-Inhibitors"},{"key":"10.1002\/14651858.CD011441.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annual Review of Immunology"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/eci.12.21","article-title":"The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor","volume":"8","author":"Matzinger","year":"2012","journal-title":"Expert Review of Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD011441.pub2-BIB0056|cit56","first-page":"726","article-title":"Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial","volume":"98","author":"Pruthi","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2516.2006.01204.x","article-title":"Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors","volume":"12","author":"Scalone","year":"2006","journal-title":"Haemophilia"},{"issue":"2 Suppl 4","key":"10.1002\/14651858.CD011441.pub2-BIB0059|cit59","first-page":"53","article-title":"The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients","volume":"31","author":"Seremetis","year":"1994","journal-title":"Seminars in Hematology"},{"issue":"5","key":"10.1002\/14651858.CD011441.pub2-BIB0060|cit60","first-page":"773","article-title":"Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery","volume":"80","author":"Shapiro","year":"1998","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011441.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2001.29506","article-title":"Inhibitor treatment: state of the art","volume":"49","author":"Shapiro","year":"2003","journal-title":"Disease-a-Month"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2516.2009.02126.x","article-title":"Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors","volume":"16","author":"Valentino","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD011441.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011441.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T08:02:30Z","timestamp":1686470550000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011441.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011441.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}